Spectrum of frontline AML induction therapies. Though most frontline regimens have not been compared directly, the chance of remission varies among frontline options. *The 7+3+midostaurin regimen (RATIFY trial⁴⁷ ) was assessed in patients aged 18 to 59 years old with FLT3-mutated AML. The RATIFY trial did not show a difference in complete remission (CR) rate between 7+3+midostaurin and 7+3 alone using the strict protocol criteria of remission achievement within 60 days. However, when expanding the response definition to include CRs during protocol treatment and within 30 days after treatment discontinuation, the CR rate was significantly higher in patients randomized to the midostaurin arm (68% vs 61%; P = .04).